No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

Woestenberg, Petra J.; King, Audrey J.; Sande, Marianne A. B. van der; Donken, Robine; Leussink, Suzan; Klis, Fiona R.M. van der; Hoebe, Christian J. P. A.; Bogaards, Johannes A.; Benthem, Birgit H B van; Adema, D.; Buist-Arkema, R.; Beerens, Anne-Sophie; Luijt, D.; Meijer, S.; Schirm, J; Buiting, A. G. M.; Peeters, M. Y. L.; Rossen, John W. A.; Verbakel, H.; Esch, P. van; Verweij, Jaco J.; Eijk, Annemiek van der; Huisman, Robin C.; Kerkhof, C.; Korff, H.; Schutten, Martin; Velzing, Jans; Verduyn-Lunel, F.; Lakbiach, S.; Rosmalen, Peter Van; Schuurman, Rob; Abma, D.; Smith, Kandice; Bruisten, Sylvia M.; Linde, Ian van der; Oostvogel, Paul M.; Touwen, C.; Vermeulen, Wilma; Brink, Antoinette A. T. P.; Nelissen, Jelly; Wolffs, Petra; Duijvendijk, N.; Schneeberger, Peter M.; Poppel, M. Dinnissen-van; Melchers, Willem J. G.; Poort, Y.; Hooghiemstra, M.; Huisman, H. G.; Weel, Jan; Bosch, Harrie C. M. van den; Haas, Tyler; Kleinspenkelink, R.; Polman, I.; Smits, Tinus; Goor, P. van; Wolfhagen, M. J. H. M.; Mooij, C. de; Koolwijk, Elly van; Peters, Michael; Swanink, C.M.A.; Tiemessen, R.; Zwet, TL van; Janssen, Jan; Pelsers, M.; Waal, W. de; Aalfs, G.; Kiewiet, Jordy J. S.; Sanders, Patricia R.; Buel-Bruins, H. van; Bokhoven-Rombouts, C. van; Cornelissen, P. J. G.; Kersten, Marie José; Ruitenbeek, C. van; Molenaar, I. Quintus; Doorn, Eva van; Masthoff, L.; Pannekoek, E.; Sigurdsson, V.; Götz, Hannelore M; Linden, M. Illidge-Onder de; Mattijssen, M.; Stam, Jord C.; Swaders, E.; Groot, F de; Postma, F.; Brouwers, Elfi E H G; Niekamp, Anne-Marie; Smit, Marieke; Botraby, A.; Bukasa, D.; Haan, C. de; Vliet, P. Hut-van; Taconis, T.; Graas, M. de; Hondelink, I.; Kampman, Carolina J. G.; Gelissen-Hansen, A.; Koning, Inge de; Kruchten, H. van; Paš, Maja; Fennema, H; Heijman, Titia; Hogewoning, Arjan; Leeuwen, Astrid van; Rooijen, M. van; Neienhuijsen, F.; Pelgrim, M.

doi:10.1016/j.jinf.2017.01.007

Cited by 23 publications

(10 citation statements)

References 25 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The qHPV and bivalent HPV vaccines are designed to cover oncogenic HPV types 16 and 18, which cause ~70% of cervical cancer cases worldwide [13] ; the qHPV vaccine also covers HPV types 6 and 11, which are responsible for 90% of genital warts cases [14] . Although partial and inconsistent cross-protection against other phylogenetically related oncogenic HPV types has been observed for both vaccines in some clinical studies, its extent, duration, and public health significance remain uncertain [7] , [11] , [15] , [16] , [17] , [18] . Population-level assessment in real-world public health programs where high coverage has occurred showed varied levels of cross-protection [16] , [17] , [18] .…”

Section: Introductionmentioning

confidence: 99%

“…Although partial and inconsistent cross-protection against other phylogenetically related oncogenic HPV types has been observed for both vaccines in some clinical studies, its extent, duration, and public health significance remain uncertain [7] , [11] , [15] , [16] , [17] , [18] . Population-level assessment in real-world public health programs where high coverage has occurred showed varied levels of cross-protection [16] , [17] , [18] . A 9-valent HPV (9vHPV; types 6/11/16/18/31/33/45/52/58) vaccine (Gardasil 9, Merck & Co., Inc., Kenilworth, NJ, USA) was developed to provide protection against the oncogenic HPV types already covered by the existing HPV vaccines (16 and 18) and extend coverage to the 5 next most common HPV types associated with cervical cancer worldwide, including Latin America (31/33/45/52/58) [13] , [19] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Ruiz-Sternberg

Moreira

Restrepo³

et al. 2018

Papillomavirus Research

View full text Add to dashboard Cite

BackgroundA 9-valent human papillomavirus (HPV6/11/16/18/31/33/45/52/58; 9vHPV) vaccine was developed to expand coverage of the previously developed quadrivalent (HPV6/11/16/18; qHPV) vaccine.MethodsEfficacy, immunogenicity, and safety outcomes were assessed in Latin American participants enrolled in 2 international studies of the 9vHPV vaccine, including a randomized, double-blinded, controlled with qHPV vaccine, efficacy, immunogenicity, and safety study in young women aged 16–26 years, and an immunogenicity and safety study in girls and boys aged 9–15 years. Participants (N=5312) received vaccination at Day 1, Month 2, and Month 6. Gynecological swabs were collected regularly in young women for cytological and HPV DNA testing. Serum was analyzed for HPV antibodies in all participants. Adverse events (AEs) were also monitored in all participants.ResultsThe 9vHPV vaccine prevented HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical, vulvar, and vaginal dysplasia with 92.3% efficacy (95% confidence interval 54.4, 99.6). Anti-HPV6, 11, 16, and 18 geometric mean titers at Month 7 were similar in the 9vHPV and qHPV vaccination groups. Anti-HPV antibody responses following vaccination were higher among girls and boys than in young women. Most (>99%) 9vHPV vaccine recipients seroconverted for all 9 HPV types at Month 7. Antibody responses to the 9 HPV types persisted over 5 years. The most common AEs were injection-site related, mostly of mild to moderate intensity.ConclusionsThe 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Latin American young women, girls, and boys. These data support 9vHPV vaccination programs in Latin America, a region with substantial cervical cancer burden.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Ruiz-Sternberg

Moreira

Restrepo³

et al. 2018

Papillomavirus Research

View full text Add to dashboard Cite

show abstract

“…Observational studies after the implementation of large-scale immunization programs are important to assess the vaccine effectiveness (VE) against both the vaccine and nonvaccine types in the population at large. Direct effectiveness measures of the bivalent vaccine from observational studies are becoming available in the Netherlands [ 11 , 12 ], as well as other countries [ 13–16 ]. These studies showed high VE from a 3-dose schedule against the vaccine types, ranging between 73% and 100% [ 12–15 ].…”

mentioning

confidence: 99%

Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors

Woestenberg

King

Benthem

et al. 2017

The Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…92 Some studies have shown cross-protection with the bivalent vaccine against low-risk serotypes with changes in incidence of condylomata acuminata although other studies have shown no impact. [93][94][95][96] Durability of seropositivity following HPV vaccination is yet to be established.…”

Section: Immunological Response To Hpv Vaccinationmentioning

confidence: 99%

“…Studies have also demonstrated cross‐protection to serotypes not included in the bivalent and quadrivalent vaccines associated to the development of cross‐reactive T‐cells and detectable serologic levels of specific antibodies to other low and high risk HPV types, as well as decreased detection of HPV prevalence in HPV types 31, 33, and 45 not included in the bivalent and quadrivalent vaccines . Some studies have shown cross‐protection with the bivalent vaccine against low‐risk serotypes with changes in incidence of condylomata acuminata although other studies have shown no impact . Durability of seropositivity following HPV vaccination is yet to be established.…”

Section: Introductionmentioning

confidence: 99%

Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology

Barroeta

Adhikari-Guragain

Grotkowski

2017

Diagnostic Cytopathology

View full text Add to dashboard Cite

Significant changes in cervical cancer screening practice, guidelines, and prevention of cervical cancer have taken place in recent years including the raising of initial cervical cancer screening age, changes in frequency of cytology screening, and the adoption of high risk HPV and cytology co-testing for some patients; the introduction of the bivalent, quadrivalent, and 9-valent HPV vaccines; and the recent approval of high risk HPV testing as primary screening with the use of cytology as triage in positive cases. This review discusses the significance of primary HPV screening, the impact of HPV vaccination in the prevalence of cervical cancer and its precursors, the interplay between high risk HPV testing and vaccination, and the implications for clinical and cytological management. Future strategies for cervical screening in the post-vaccination era are also discussed.

show abstract

No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors

Abstract: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW.

Cited by 23 publications

References 25 publications

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women

Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors

Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology

Contact Info

Product

Resources

About